Qing Xi Ooi supports clients with hands-on analysis and strategic advice

Viviana Moroso brings scientific depth to quality control

Siv Jönsson develops Pharmetheus’s learning agenda
Events
News

Contact us

Home
About us
People
Moriah Pellowe

Moriah Pellowe

Moriah Pellowe, Ph.D.

Director, MIDD Consultant

Google scholar

Joined Pharmetheus in 2021, actively working in client projects
Expertise includes physiological based pharmacokinetic modeling (PBPK) and mathematical modeling in therapeutic areas such as oncology
Previously worked as Postdoctoral Fellow at the University of Waterloo, Canada, where she developed a mechanistic inhalation model for drug disposition and an R-package for virtual bioequivalence testing to inform clinical trial design supported by a grant from the FDA, and as Sessional Lecturer at the University of Waterloo, Canada
B.Sc. in Mathematics (2014) from Redeemer University, Canada, and Ph.D. in Applied Mathematics (2020) from the University of Waterloo, Canada

Pharmetheus affiliated publications

Coproporphyrin I PBPK model in the open systems pharmacology suite enables precise prediction of OATP 1B- mediated drug interactions through calibrated In vivo inhibition constants Accelerating subcutaneous drug development: A mechanistic absorption model for the Open Systems Pharmacology framework Benchmarking a mechanistic immunogenicity framework: aligning sequence-based epitope predictions with clinical observations PBPK workflow for predicting clinical DDI risk of OATP1B1/3 inhibitors utilizing the CP-I biomarker: A case study with cyclosporine A An Open-Source Framework for Virtual Bioequivalence Modeling and Clinical Trial Design Physiologically-based pharmacokinetic modeling to support submission of brigimadlin (BI 907828) in dedifferentiated liposarcoma A quantitative systems pharmacology framework of immunogenicity to propose mitigation strategies after subcutaneous administration Absorption, Bioavailability, and Immunogenicity after Subcutaneous Administration: Evaluation of a Subcutaneous Platform within the Open Systems Pharmacology framework Development of a Physiologically-Based Pharmacokinetic Model for Coproporphyrin I (CP-I) Using the Open Systems Pharmacology Software Suite (PK-Sim and MoBi) for assessment of OATP1B-based DDIs Mechanistic modelling of bioavailability and local immunogenicity after subcutaneous administration within the Open Systems Pharmacology framework Physiologically based pharmacokinetic (PBPK) modelling of cabotegravir (CAB) to support design of microarray patches (MAPs) for the treatment of HIV positive children A platform for mechanistic modelling of subcutaneous administration with the effect of immunogenicity within the Open Systems Pharmacology framework

Contact

Pharmetheus AB
Kungsängstull 4  
753 19 Uppsala, Sweden

Visiting address:  
Dragarbrunnsgatan 77, 5th floor

LinkedIn
YouTube

Science & Services
Quick links

About Pharmetheus

Pharmetheus is a consultancy firm helping clients reduce uncertainty in technical and regulatory processes, increasing confidence in the development of new medicines that can improve patients’ lives.

Whistleblower
Privacy Policy
Cookie Policy